Scope of this summary
Adults with severe alopecia areata being considered for baricitinib by a clinician experienced in systemic immunomodulation. Pediatric use for alopecia areata and combination with another JAK inhibitor, biologic immunomodulator or potent immunosuppressant are outside the labeled pathway.
The Bottom Line
- Confirm severe alopecia areata, document scalp and eyebrow or eyelash involvement and exclude infection, scarring alopecia and other causes before exposing the patient to systemic immunomodulation.
- The FDA label indicates baricitinib for adults with severe alopecia areata; select the lowest labeled dose that achieves and maintains response and follow current label adjustments for renal function and interacting medicines.
- Before treatment, evaluate tuberculosis and viral hepatitis, complete the label-required blood counts and hepatic or renal assessment, review infection and malignancy history and update immunizations without giving live vaccine during treatment.
- Use shared decision-making around expected regrowth, delayed response, likely need for maintenance, reproductive considerations and serious infection, mortality, malignancy, major cardiovascular-event and thrombosis warnings.
- The June 2026 FDA safety supplement adds hypoglycemia risk for patients with diabetes after starting JAK/STAT inhibitors; increase glucose awareness or monitoring and review glucose-lowering therapy when clinically indicated.
Practical clinical workflow
1
Verify adult age, severe active alopecia areata, baseline SALT or equivalent extent, brows, lashes, nails, duration, prior treatment, comorbidity, smoking and cardiovascular or thrombotic risk.
2
Screen for active and latent tuberculosis, hepatitis and serious infection; obtain the label-required baseline complete blood count, hepatic and renal assessment, reconcile interacting medicines, and plan lipid assessment at approximately 12 weeks.
3
Update nonlive vaccines, counsel on infection and thrombotic symptoms, pregnancy and lactation, skin-cancer surveillance and diabetic hypoglycemia, then prescribe only from the current FDA label.
4
Reassess laboratory safety and clinical response at the label-appropriate intervals, documenting scalp and non-scalp regrowth, adverse events, infections and whether dose reduction after a sustained adequate response is appropriate.
5
Interrupt or stop treatment according to the label for serious infection, hematologic or hepatic abnormality, hypersensitivity, thrombosis or another serious adverse event; reassess benefit when meaningful regrowth is not achieved.
Safety boundaries and escalation
- Do not initiate during an active serious infection or active tuberculosis; interrupt for a serious or opportunistic infection and investigate as an immunocompromised host.
- Assess individual malignancy, smoking, cardiovascular and thrombosis risk before and during treatment; chest pain, focal neurologic symptoms or suspected venous thromboembolism requires urgent evaluation.
- Follow current FDA thresholds for anemia, lymphopenia, neutropenia, liver injury and renal impairment.
- In patients with diabetes, warn about new hypoglycemia, increase glucose monitoring when appropriate and coordinate prompt adjustment of glucose-lowering therapy rather than simply discontinuing monitoring after initiation.
Localization
FDA labeling defines lawful use; insurer prior authorization is an administrative layer and must not be misrepresented as a clinical guideline. The June 2026 prescribing information and safety supplement were directly checked on 2026-08-20 and must be rechecked before prescribing and at each scheduled review.
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- U.S. Food and Drug AdministrationOLUMIANT (baricitinib) tablets, for oral use — Prescribing InformationNDA 207924/S-011 · Revised June 2026; includes the alopecia-areata indication and 2026 hypoglycemia warning · updated 2026-06-30 · accessed 2026-08-20view source
- U.S. Food and Drug AdministrationOlumiant (baricitinib) NDA 207924/S-11 Supplement ApprovalNDA 207924/S-11 · Reference ID 5826077 · June 2026 labeling revision for hypoglycemia risk in patients with diabetes · published 2026-06-30 · accessed 2026-08-20view source
- American Academy of DermatologyAlopecia areata: Diagnosis and treatmentaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.